Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: Acute and mid-term effects

European Heart Journal

Volumn 25, Issue 5, 2004, Pages 431-436

  Mikhail, Ghada W ^a   Prasad, Sanjay K ^a   Li, Wei ^a   Rogers, Paula ^a   Chester, Adrian H ^b   Bayne, Stephanie ^a   Stephens, David ^c   Khan, Mohammed ^b   Gibbs, J S R ^b   Evans, Timothy W ^a   Mitchell, Andrew ^a   Yacoub, Magdi H ^b   Gatzoulis, Michael A ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Pulmonary hypertension; Sitdenafil

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; SILDENAFIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; HEART CATHETERIZATION; HEART OUTPUT; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; VISUAL DISORDER; WALKING;

ADMINISTRATION, ORAL; ADULT; BLOOD PRESSURE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; VASCULAR RESISTANCE;

EID: 12144286644     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2004.01.013     Document Type: Article

References (24)

1. Sitbon O, Humbert M, Simonneau G. Primary pulmonary hypertension: current therapy. Prog Cardiovasc Dis 2002;45:115-28.
2. Hoeper MM, Schwarze M, Ehlerding S et al. Long-term treatment of primary pulmonary hypertension with aerosolised iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866-70.
3. Gatie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis 2002;45:213-24.
4. Lepore JJ, Maroo A, Pereira et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002;90:677-80.
5. Zhao L, Mason NA, Morrell NW et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001;104:424-8.
6. Weimann J, Ullrich R, Hromi J et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anaesthesiology 2000;92:1702-12.
7. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000;343:1342.
8. Wensel R, Optiz CF, Anker SD et al. Assessment of survival in patients with primary pulmonary hypertension. Importance of cardiopulmonary exercise testing. Circulation 2002;106:319-24.
9. Sun XG, Hansen JE, Oudiz RJ et al. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001; 104:429-35.
10. Ryan T, Petrovic O, Dillon JC et al. An echocardiographic index for separation of right ventricular volume and pressure overload. J Am Coll Cardiol 1985;5:918-27.
11. Louie EK, Rich S, Brundage BH. Doppler echocardiographic assessment of impaired left ventricular filling in patients with right ventricular pressure overload due to primary pulmonary hypertension. J Am Coll Cardiol 1986;8:1298-306.
12. Stojnic BB, Brecker SJ, Xiao HB et al. Left ventricular filling characteristics in pulmonary hypertension: a new mode of ventricular interaction. Br Heart J 1992;68:16-20.
13. Ware JE, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36. Med Care 1992;304:73-83.
14. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research work in progress. Circulation 2000;102:2781-91.
15. Michelakis E, Tymchak W, Lien D et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Comparison with nitric oxide. Circulation 2002;105:2398-403.
16. Wilkens H, Guth A, Konig J et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104:1218-22.
17. Sastry BK, Narasimhan C, Reddy NK et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J 2002;54:410-4.
18. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002;45:173-202.
19. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;21:780-8.
20. Gibbs JS, Wharton J, Wilkins MR. Pulmonary arterial hypertension and the vasoconstrictive factor: is there still a role for vasodilator testing? Eur Heart J 2003;24:297-8.
21. Dabestani A, Mahan G, Gardin JM et al. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. Am J Cardiol 1987;59(6):662-8.
22. Kitabatake A, Inoue M, Asao M et al. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation 1983;68:302-9.
23. Ghofrani HA, Wiedemann R, Rose F et al. Sildenafil for the treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360:895-900.
24. Stiebellehner L, Petkov V, Vonbank K et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003;123: 1293-5.